c red k UN dang pharmaceutical
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
Hypertension and Dyslipidemia
CKD-386(5)
D013, Daat, Daah
Phase 1
An open label, randomized, single dose, 2-sequence, 4-period, cross-over clinical trial to evaluate the pharmacokinetics and the tolerability of CKD-386(5) with co-administration of D013, D326, and D337 in healthy adult volunteers}}
Study Type : | Interventional |
Estimated Enrollment : | 63 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and the Tolerability of CKD-386(5) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers |
Actual Study Start Date : | July 17, 2023 |
Estimated Primary Completion Date : | September 1, 2023 |
Estimated Study Completion Date : | September 26, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Sequence 1 Period 1: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 2: CKD-386(5)- A single oral dose of 1 tablet under fasting condition Period 3: D013, D326, D337- A single oral dose of 3tablets under fasting condition Period 4: CKD-386(5)- A single oral dose of 1 tablet under fasting condition |
Drug: CKD-386(5) Drug: D013, D326, D337 |
Experimental: Sequence 2 Period 1: CKD-386(5)- A single oral dose of 1 tablet under fasting condition Period 2: D013, D326, D337- A single oral dose of 3 tablets under fasting condition Period 3: CKD-386(5)- A single oral dose of 1 tablet under fasting condition Period 4: D013, D326, D337- A single oral dose of 3 tablets under fasting condition |
Drug: CKD-386(5) Drug: D013, D326, D337 |
Ages Eligible for Study: | 19 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
H plus Yangji hospital
Seoul, Korea, Republic of,